Utility of Endoscopy in Hospitalized Patients with Gastrointestinal Hemorrhage and Pulmonary Hypertension.
Adolescent
Adult
Aged
Databases, Factual
Endoscopy, Gastrointestinal
/ adverse effects
Female
Gastrointestinal Hemorrhage
/ diagnosis
Health Care Costs
/ trends
Hemostasis, Endoscopic
/ adverse effects
Hospital Mortality
/ trends
Humans
Hypertension, Pulmonary
/ diagnosis
Inpatients
Length of Stay
/ trends
Male
Middle Aged
Prevalence
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
United States
/ epidemiology
Young Adult
Endoscopy
Gastrointestinal hemorrhage
Pulmonary hypertension
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
12
08
2020
accepted:
17
12
2020
pubmed:
12
1
2021
medline:
15
12
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Gastrointestinal hemorrhage (GIH) has been reported as one of the most common GI complications in patients with pulmonary hypertension (PH). There is paucity of data on the national burden of GIH in patients with PH. We aimed to assess the prevalence, trends and outcomes of endoscopic interventions in patients with PH who were admitted with GIH. We queried National Inpatient Sample (NIS) database from 2005 to 2014 and identified the patients hospitalized with primary or secondary discharge diagnosis of PH (ICD 9 CM Code: 416.0, 416.8, and 416.9). Using Clinical Classification Software Coding system (153) patients with concurrent diagnosis of GIH were then identified. We studied the prevalence and trends of GIH in PH, factors associated with GIH, use of endoscopy, factors associated with utilization of endoscopic interventions, endoscopy outcomes including mortality, and overall healthcare burden. Out of 7,586,973 PH hospitalizations 3.2% (N = 246,358) had concurrent GIH, with a rising prevalence of GIH in PH patients during the last decade. Clinical predictors for GIH in PH included older age, congestive heart failure, anticoagulation therapy and concurrent alcohol abuse. Mean length of stay (LOS) in PH patients hospitalized with GIH was significantly higher than without GIH (8.6 vs. 6.4 days, p < 0.01) along with a significant increase in hospitalization cost ($20,189 vs. $14,807, p < 0.01). Similarly, odds of in-hospital mortality increase by ~ 1.5 times in PH patients with GIH than those without it (adjusted odds ratio [aOR: 1.45, 95%CI: 1.43-1.47]). Endoscopic interventions were performed in 48.6% of patients with PH and GIH during their hospitalization. Older patients were more likely to undergo endoscopy, as well as the patients who received blood transfusion, and those with hypovolemic shock. Patients with acute respiratory failure and acute renal failure were less likely to get endoscopy. Mean LOS in patients undergoing endoscopic intervention was significantly higher than those who did not receive any intervention (8.7 vs. 8.4 days, p < 0.01), without a substantial increase in hospitalization cost ($20,344 vs. $20,041, p < 0.01). Also, there was a significant decrease in in-hospital mortality in patients undergoing endoscopic interventions. Concurrent GIH in patients with PH increases length of stay; healthcare costs and increases in-hospital mortality. Use of endoscopic interventions in these patients is associated with reduced length of stay, in-hospital mortality without significantly increasing the overall health care burden and should be considered in hospitalized patients with PH who are admitted with GIH. Future studies comparing GIH patients with and without PH should be done to assess if PH is a risk factor for worse outcomes. No IRB required due to use of national de-identified data.
Sections du résumé
BACKGROUND
Gastrointestinal hemorrhage (GIH) has been reported as one of the most common GI complications in patients with pulmonary hypertension (PH). There is paucity of data on the national burden of GIH in patients with PH. We aimed to assess the prevalence, trends and outcomes of endoscopic interventions in patients with PH who were admitted with GIH.
METHOD
We queried National Inpatient Sample (NIS) database from 2005 to 2014 and identified the patients hospitalized with primary or secondary discharge diagnosis of PH (ICD 9 CM Code: 416.0, 416.8, and 416.9). Using Clinical Classification Software Coding system (153) patients with concurrent diagnosis of GIH were then identified. We studied the prevalence and trends of GIH in PH, factors associated with GIH, use of endoscopy, factors associated with utilization of endoscopic interventions, endoscopy outcomes including mortality, and overall healthcare burden.
RESULTS
Out of 7,586,973 PH hospitalizations 3.2% (N = 246,358) had concurrent GIH, with a rising prevalence of GIH in PH patients during the last decade. Clinical predictors for GIH in PH included older age, congestive heart failure, anticoagulation therapy and concurrent alcohol abuse. Mean length of stay (LOS) in PH patients hospitalized with GIH was significantly higher than without GIH (8.6 vs. 6.4 days, p < 0.01) along with a significant increase in hospitalization cost ($20,189 vs. $14,807, p < 0.01). Similarly, odds of in-hospital mortality increase by ~ 1.5 times in PH patients with GIH than those without it (adjusted odds ratio [aOR: 1.45, 95%CI: 1.43-1.47]). Endoscopic interventions were performed in 48.6% of patients with PH and GIH during their hospitalization. Older patients were more likely to undergo endoscopy, as well as the patients who received blood transfusion, and those with hypovolemic shock. Patients with acute respiratory failure and acute renal failure were less likely to get endoscopy. Mean LOS in patients undergoing endoscopic intervention was significantly higher than those who did not receive any intervention (8.7 vs. 8.4 days, p < 0.01), without a substantial increase in hospitalization cost ($20,344 vs. $20,041, p < 0.01). Also, there was a significant decrease in in-hospital mortality in patients undergoing endoscopic interventions.
CONCLUSION
Concurrent GIH in patients with PH increases length of stay; healthcare costs and increases in-hospital mortality. Use of endoscopic interventions in these patients is associated with reduced length of stay, in-hospital mortality without significantly increasing the overall health care burden and should be considered in hospitalized patients with PH who are admitted with GIH. Future studies comparing GIH patients with and without PH should be done to assess if PH is a risk factor for worse outcomes.
CLINICAL TRIAL REGISTRATION NUMBER
No IRB required due to use of national de-identified data.
Identifiants
pubmed: 33428039
doi: 10.1007/s10620-020-06803-4
pii: 10.1007/s10620-020-06803-4
pmc: PMC9206875
mid: NIHMS1799919
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4159-4168Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK083251
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Références
Prev Med. 2016 Jul;88:196-202
pubmed: 27095325
Prev Chronic Dis. 2017 Apr 13;14:E31
pubmed: 28409741
Best Pract Res Clin Gastroenterol. 2019 Oct - Dec;42-43:101610
pubmed: 31785737
World J Gastrointest Pathophysiol. 2016 Feb 15;7(1):86-96
pubmed: 26909231
Gastroenterology. 2017 Apr;152(5):1014-1022.e1
pubmed: 28043907
Eur Respir J. 2013 Apr;41(4):872-8
pubmed: 22936704
Pulm Circ. 2017 Jul-Sep;7(3):692-701
pubmed: 28677986
Chest. 2007 Jun;131(6):1917-28
pubmed: 17565025
Gastrointest Endosc. 2015 Apr;81(4):882-8.e1
pubmed: 25484324
Eur J Clin Invest. 2009 Jun;39 Suppl 2:68-73
pubmed: 19335748
Gut. 2019 May;68(5):776-789
pubmed: 30792244
Gut. 2011 Oct;60(10):1327-35
pubmed: 21490373
World J Gastroenterol. 2016 Jan 7;22(1):446-66
pubmed: 26755890
Thorax. 1979 Apr;34(2):281-3
pubmed: 483201
Dig Dis Sci. 2019 Jun;64(6):1588-1598
pubmed: 30519853
Dig Dis Sci. 2015 Dec;60(12):3697-706
pubmed: 26072320
Aliment Pharmacol Ther. 2012 Sep;36(6):542-50
pubmed: 22817655
Dig Dis Sci. 2018 May;63(5):1286-1293
pubmed: 29282637
Aliment Pharmacol Ther. 2011 Mar;33(5):585-91
pubmed: 21205256
Curr Hypertens Rep. 2018 Oct 5;20(12):99
pubmed: 30291516